Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19

Status: Suspended

Phase of Trial: Phase II/III

Latest Information Update: 24 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Paridiprubart (Primary)
Indications COVID-19 respiratory infection
Focus Therapeutic Use
Sponsors Edesa Biotech

Most Recent Events

13 Dec 2024 According to an Edesa Biotech media release, company anticipates topline results for this Phase 2 study could be available within as few as 12 to 18 months following regulatory clearance in the U.S.
14 Nov 2024 Status changed from recruiting to suspended.
28 Jul 2023 Planned End Date changed from 1 Apr 2021 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com